Indiana hospitals achieve Stage 7

HIMSS Analytics has awarded three hospitals of the Munster, Ind.-based Community Healthcare System with Stage 7 of its EMR Adoption Model.

Stage 7 is the highest level of the model, representing an advanced patient record environment. During the second quarter of 2015, only 3.7 percent of the more than 5,400 U.S. hospitals in the HIMSS Analytics Database received the Stage 7 Award. 

"The achievement of HIMSS Level 7 builds upon a long history of our hospitals using technology to improve the quality, safety and efficiency of care," said John Gorski, president and CEO of Community Healthcare System. "Through the process of integrating an electronic medical record system and leveraging other advances in information technology, Community Healthcare System has become a much more data-driven organization. Most importantly, we are using these new technologies to better engage our patients and the medical community in understanding how best to bring about improvements in healthcare."

The Community Healthcare System hospitals will be recognized at the 2016 HIMSS Conference & Exhibition beginning Feb. 29 in Las Vegas.

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.